SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
FDA
Prasad Out at CBER Following Sarepta Rollercoaster and Conservative Criticism
The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, where he had been the head of the Center for Biologics Evaluation and Research for less than three months.
July 29, 2025
 · 
1 min read
 · 
Heather McKenzie
Facade of AstraZeneca's office in Shanghai, China
Earnings
AstraZeneca CEO Says World ‘Needs to Share’ in Global Pharma R&D
Pascal Soriot’s comments came during AstraZeneca’s Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, with its cancer portfolio driving earnings despite clinical roadblocks.
July 29, 2025
 · 
3 min read
 · 
Tristan Manalac
Creative collage picture human hands hold scissors banknote cash cut money inflation crisis funds salary devaluation drawing background.
Earnings
Merck Cuts $3B to Support Aggressive Launch Schedule, Late-Stage R&D
CEO Rob Davis referred to the cost reduction program as a ‘reallocation’ rather than a cut, with the savings to be reinvested to support up to 20 new product launches.
July 29, 2025
 · 
3 min read
 · 
Annalee Armstrong
Facade of Novo Nordisk's office in Fremont, California
C-suite
Novo Nordisk Names New Leader, Cuts 2025 Sales Guidance By 5%
In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its semaglutide franchise in the U.S.—and named current international operations head Maziar Mike Doustdar as its new president and CEO.
July 29, 2025
 · 
2 min read
 · 
Heather McKenzie
External view of the U.S. Capitol building
Regulatory
Senate Democrats Investigating HHS Secretary Kennedy’s ACIP Firing
Six weeks after HHS Secretary RFK Jr. cited unexplained conflicts of interest in dismissing all 17 members of the CDC’s vaccine advisory committee, Democrats are asking for details.
July 29, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Inclusion of new taxes into the price and increase in cost. Include inflation and costs for pricing. Increase in cost of electricity, fuel, increase in wages for workers or theft in the store.
Tariffs
15% Tariffs Come to Pharma in New EU Trade Deal
While some analysts forecast the tariffs could mean billions in additional industry expenditure, others expect the overall impact to be “manageable.”
July 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Vaccines
RFK Jr. Looks to Overhaul ‘Broken’ Vaccine Injury Compensation Program
In a post on X, Health Secretary Robert F. Kennedy Jr. alleged that the Vaccine Injury Compensation Program has “devolved into a morass of inefficiency, favoritism, and outright corruption.”
July 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Red and White Cartoon Spaceship Flying on Blue Background with Copy Space 3D Illustration
Startups
BMS, Bain Birth Biotech for Autoimmune Disorders
BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus erythematosus and plaque psoriasis, and $300 million in funds from Bain Capital.
July 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Planning strategy and ways to achieve business goals, searching for new opportunities for high results, direction of career development, the path to great success, man changes direction on signpost.
Gene therapy
FDA Does 180 on Sarepta, Freeing DMD Gene Therapy for Ambulatory Patients
The swift FDA action removes an overhang from Sarepta and allows Elevidys to return to the market without another safety study, as had been feared, Jefferies analysts said Monday.
July 28, 2025
 · 
2 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS